What Researchers Did
Researchers conducted a randomized controlled trial to evaluate hyperbaric oxygen therapy combined with pharmacologic treatment for keratoendotheliosis secondary to surgical treatment.
What They Found
Of 33 patients, 12 received hyperbaric oxygen daily for ten days alongside pharmacologic therapy, while 21 received pharmacologic therapy alone. Hyperbaric oxygen treatment effectively reduced corneal edema, especially when administered early, and prevented corneal neovascularization in all treated patients.
What This Means for Canadian Patients
Canadian patients with post-surgical keratoendotheliosis might benefit from hyperbaric oxygen therapy to reduce corneal swelling and prevent new blood vessel formation. Early administration of this therapy could be particularly beneficial for improving outcomes.
Canadian Relevance
This study does not report any direct Canadian connection or involvement.
Study Limitations
Limitations include the small sample size of 33 patients and the imbalance between the two treatment arms.